- Home
- LGND vs ADPT Comparison
LGND vs ADPT Comparison
Compare LGND & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- ADPT
- Stock Information
- Founded
- LGND 1987
- ADPT 2009
- Country
- LGND United States
- ADPT United States
- Employees
- LGND N/A
- ADPT N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGND Health Care
- ADPT Health Care
- Exchange
- LGND Nasdaq
- ADPT Nasdaq
- Market Cap
- LGND 2.0B
- ADPT 1.8B
- IPO Year
- LGND 1992
- ADPT 2019
- Fundamental
- Price
- LGND $124.30
- ADPT $11.06
- Analyst Decision
- LGND Strong Buy
- ADPT Strong Buy
- Analyst Count
- LGND 8
- ADPT 7
- Target Price
- LGND $144.71
- ADPT $10.57
- AVG Volume (30 Days)
- LGND 139.7K
- ADPT 2.4M
- Earning Date
- LGND 08-05-2025
- ADPT 07-31-2025
- Dividend Yield
- LGND N/A
- ADPT N/A
- EPS Growth
- LGND N/A
- ADPT N/A
- EPS
- LGND N/A
- ADPT N/A
- Revenue
- LGND $181,488,000.00
- ADPT $189,527,000.00
- Revenue This Year
- LGND $18.41
- ADPT $24.46
- Revenue Next Year
- LGND $18.87
- ADPT $20.25
- P/E Ratio
- LGND N/A
- ADPT N/A
- Revenue Growth
- LGND 53.40
- ADPT 8.61
- 52 Week Low
- LGND $81.74
- ADPT $3.85
- 52 Week High
- LGND $129.90
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- LGND 64.68
- ADPT 54.86
- Support Level
- LGND $120.68
- ADPT $11.35
- Resistance Level
- LGND $127.07
- ADPT $12.36
- Average True Range (ATR)
- LGND 3.76
- ADPT 0.59
- MACD
- LGND 0.86
- ADPT -0.08
- Stochastic Oscillator
- LGND 81.95
- ADPT 41.05
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).